2
|
Melemed AS, Larson T, Dudek AZ, Mellskog CE, Bloss LP, Ye Z, Obasaju CK. Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: Second dosing schedule & response. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7257] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. S. Melemed
- Eli Lilly & Co; Hubert Humphrey Cancer Ctr, Robbinsdale, MN; Univ of Minnesota Comprehensive Cancer Ctr, Minneapolis, MN; Univ of Minnesota Comprehensive Cancer Cent, Minneapolis, MN; Eli Lilly & Co, Indianapolis, IN
| | - T. Larson
- Eli Lilly & Co; Hubert Humphrey Cancer Ctr, Robbinsdale, MN; Univ of Minnesota Comprehensive Cancer Ctr, Minneapolis, MN; Univ of Minnesota Comprehensive Cancer Cent, Minneapolis, MN; Eli Lilly & Co, Indianapolis, IN
| | - A. Z. Dudek
- Eli Lilly & Co; Hubert Humphrey Cancer Ctr, Robbinsdale, MN; Univ of Minnesota Comprehensive Cancer Ctr, Minneapolis, MN; Univ of Minnesota Comprehensive Cancer Cent, Minneapolis, MN; Eli Lilly & Co, Indianapolis, IN
| | - C. E. Mellskog
- Eli Lilly & Co; Hubert Humphrey Cancer Ctr, Robbinsdale, MN; Univ of Minnesota Comprehensive Cancer Ctr, Minneapolis, MN; Univ of Minnesota Comprehensive Cancer Cent, Minneapolis, MN; Eli Lilly & Co, Indianapolis, IN
| | - L. P. Bloss
- Eli Lilly & Co; Hubert Humphrey Cancer Ctr, Robbinsdale, MN; Univ of Minnesota Comprehensive Cancer Ctr, Minneapolis, MN; Univ of Minnesota Comprehensive Cancer Cent, Minneapolis, MN; Eli Lilly & Co, Indianapolis, IN
| | - Z. Ye
- Eli Lilly & Co; Hubert Humphrey Cancer Ctr, Robbinsdale, MN; Univ of Minnesota Comprehensive Cancer Ctr, Minneapolis, MN; Univ of Minnesota Comprehensive Cancer Cent, Minneapolis, MN; Eli Lilly & Co, Indianapolis, IN
| | - C. K. Obasaju
- Eli Lilly & Co; Hubert Humphrey Cancer Ctr, Robbinsdale, MN; Univ of Minnesota Comprehensive Cancer Ctr, Minneapolis, MN; Univ of Minnesota Comprehensive Cancer Cent, Minneapolis, MN; Eli Lilly & Co, Indianapolis, IN
| |
Collapse
|
3
|
Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A, Pawlicki M, Melemed AS, O'Shaughnessy J, Reyes JM. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.510] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. S. Albain
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - S. Nag
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - G. Calderillo-Ruiz
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - J. P. Jordaan
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - A. Llombart
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - A. Pluzanska
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - M. Pawlicki
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - A. S. Melemed
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - J. O'Shaughnessy
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| | - J. M. Reyes
- Loyola University Chicago Med Ctr, Maywood, IL; Inlaks and Budhrani Hospital, Pune, Maharashtra, India; Instituto Nacional De Cancerologia, Thalpan, Mexico; Addington Hospital, Durban, South Africa; Instituto Valenciano De Oncologia, Valencia, Spain; Klinika Chemioterapii, Lodz, Poland; Center of Oncology, Krakow, Poland; Baylor-Sammons Cancer Center, Dallas, TX; Clinicas Las Condes, Santiago, Chile
| |
Collapse
|